Product Description
a TLR9 agonist for cancer treatment being developed by Merck KGaA, Darmstadt, Germany, under its collaboration with Idera.Ê (Sourced from: https://ir.iderapharma.com/news-releases/news-release-details/idera-pharmaceuticals-provides-update-imo-2055-clinical)
Mechanisms of Action: TLR9 Agonist
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: EMD Serono
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Head and Neck Cancer|Squamous Cell Carcinoma|Renal Cell Carcinoma
Phase 1: Non-Small-Cell Lung Cancer|Colorectal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
R/M SCCHN | P2 |
Completed |
Squamous Cell Carcinoma|Head and Neck Cancer |
2012-01-01 |
|
IMO-2055-210 | P1 |
Terminated |
Colorectal Cancer |
2011-04-01 |
|
EMR 200068-200 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2010-10-01 |
|
NCT00729053 | P2 |
Completed |
Renal Cell Carcinoma |
2008-04-01 |